Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis
Selective depletion of CD20 + B cells by anti-CD20 monoclonal antibodies as monotherapy in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and signifies an important advance in the treatment of relapsing-remitting MS. Ocrelizumab, a humanized anti-CD20 monoclonal an...
Gespeichert in:
| Veröffentlicht in: | Neurotherapeutics 2017-10, Vol.14 (4), p.835-841 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 841 |
|---|---|
| container_issue | 4 |
| container_start_page | 835 |
| container_title | Neurotherapeutics |
| container_volume | 14 |
| creator | Gelfand, Jeffrey M. Cree, Bruce A. C. Hauser, Stephen L. |
| description | Selective depletion of CD20
+
B cells by anti-CD20 monoclonal antibodies as monotherapy in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and signifies an important advance in the treatment of relapsing-remitting MS. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, is also the first proven therapy to lessen disability progression in primary progressive MS—a breakthrough for patients with a disease that had no proven therapy. Ocrelizumab is generally well tolerated, with the most common adverse events experienced being infusion reactions and infections. In ocrelizumab trials in MS a numerical imbalance in the risk of malignancies was observed. In this article, we review advances in anti-CD20 B-cell-depleting biological therapies for MS, including ocrelizumab, rituximab, and ofatumumab. |
| doi_str_mv | 10.1007/s13311-017-0557-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5722762</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1917963040</sourcerecordid><originalsourceid>FETCH-LOGICAL-c536t-c96e3d73a617d50b3f4727d57fd49b5f54e137f590e35696720c78520c9a2af3</originalsourceid><addsrcrecordid>eNp1kU9P3DAQxa2qqLts-QC9VJG4VEIG_83EFyS60IK01R7Yu-VNJotX2WSxk0rl02MUQIDUiz3S-80bjx8h3zg75YzBWeRSck4ZB8q0Bqo-kSkvoKCgwHxOtZGSguByQg5j3DKmpTTFFzIRRW60Aj4li2UZsPEPw86tM9dW2bK_w5DNLwU7yX7SOTYNvcR9g71vN9kqaW7vMWa-zf4MTe-Tkt2WDYYu-viVHNSuiXj0fM_I6tfVan5NF8vfN_OLBS21zHtamhxlBdLlHCrN1rJWIFIFdaXMWtdaIZdQa8NQ6tzkIFgJhU6nccLVckbOR9v9sN5hVWLbB9fYffA7F_7Zznn7Xmn9nd10f60GISAXyeDHs0Ho7geMvd35WKZVXYvdEC03HEwumWIJPf6AbrshtGm7RIHSko2GfKTK9A8xYP36GM7sU1R2jMqmqOxTVFalnu9vt3jteMkmAWIEYpLaDYY3o__r-ggJu50g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1974530762</pqid></control><display><type>article</type><title>Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Gelfand, Jeffrey M. ; Cree, Bruce A. C. ; Hauser, Stephen L.</creator><creatorcontrib>Gelfand, Jeffrey M. ; Cree, Bruce A. C. ; Hauser, Stephen L.</creatorcontrib><description>Selective depletion of CD20
+
B cells by anti-CD20 monoclonal antibodies as monotherapy in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and signifies an important advance in the treatment of relapsing-remitting MS. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, is also the first proven therapy to lessen disability progression in primary progressive MS—a breakthrough for patients with a disease that had no proven therapy. Ocrelizumab is generally well tolerated, with the most common adverse events experienced being infusion reactions and infections. In ocrelizumab trials in MS a numerical imbalance in the risk of malignancies was observed. In this article, we review advances in anti-CD20 B-cell-depleting biological therapies for MS, including ocrelizumab, rituximab, and ofatumumab.</description><identifier>ISSN: 1933-7213</identifier><identifier>ISSN: 1878-7479</identifier><identifier>EISSN: 1878-7479</identifier><identifier>DOI: 10.1007/s13311-017-0557-4</identifier><identifier>PMID: 28695471</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Antibodies, Monoclonal, Humanized - therapeutic use ; Antigens, CD20 - immunology ; B-Lymphocytes - drug effects ; B-Lymphocytes - immunology ; Biomedical and Life Sciences ; Biomedicine ; CD20 antigen ; Clinical trials ; Clinical Trials as Topic ; Disease Progression ; Humans ; Immunologic Factors - therapeutic use ; Immunomodulators ; Immunotherapy ; Lymphocytes B ; Monoclonal antibodies ; Multiple sclerosis ; Multiple Sclerosis - drug therapy ; Multiple Sclerosis - immunology ; Neurobiology ; Neurology ; Neurosciences ; Neurosurgery ; Review ; Rituximab ; Targeted cancer therapy ; Treatment Outcome</subject><ispartof>Neurotherapeutics, 2017-10, Vol.14 (4), p.835-841</ispartof><rights>The American Society for Experimental NeuroTherapeutics, Inc. 2017</rights><rights>Neurotherapeutics is a copyright of Springer, (2017). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c536t-c96e3d73a617d50b3f4727d57fd49b5f54e137f590e35696720c78520c9a2af3</citedby><cites>FETCH-LOGICAL-c536t-c96e3d73a617d50b3f4727d57fd49b5f54e137f590e35696720c78520c9a2af3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722762/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722762/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28695471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gelfand, Jeffrey M.</creatorcontrib><creatorcontrib>Cree, Bruce A. C.</creatorcontrib><creatorcontrib>Hauser, Stephen L.</creatorcontrib><title>Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis</title><title>Neurotherapeutics</title><addtitle>Neurotherapeutics</addtitle><addtitle>Neurotherapeutics</addtitle><description>Selective depletion of CD20
+
B cells by anti-CD20 monoclonal antibodies as monotherapy in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and signifies an important advance in the treatment of relapsing-remitting MS. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, is also the first proven therapy to lessen disability progression in primary progressive MS—a breakthrough for patients with a disease that had no proven therapy. Ocrelizumab is generally well tolerated, with the most common adverse events experienced being infusion reactions and infections. In ocrelizumab trials in MS a numerical imbalance in the risk of malignancies was observed. In this article, we review advances in anti-CD20 B-cell-depleting biological therapies for MS, including ocrelizumab, rituximab, and ofatumumab.</description><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antigens, CD20 - immunology</subject><subject>B-Lymphocytes - drug effects</subject><subject>B-Lymphocytes - immunology</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>CD20 antigen</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Disease Progression</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Immunomodulators</subject><subject>Immunotherapy</subject><subject>Lymphocytes B</subject><subject>Monoclonal antibodies</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple Sclerosis - immunology</subject><subject>Neurobiology</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Neurosurgery</subject><subject>Review</subject><subject>Rituximab</subject><subject>Targeted cancer therapy</subject><subject>Treatment Outcome</subject><issn>1933-7213</issn><issn>1878-7479</issn><issn>1878-7479</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kU9P3DAQxa2qqLts-QC9VJG4VEIG_83EFyS60IK01R7Yu-VNJotX2WSxk0rl02MUQIDUiz3S-80bjx8h3zg75YzBWeRSck4ZB8q0Bqo-kSkvoKCgwHxOtZGSguByQg5j3DKmpTTFFzIRRW60Aj4li2UZsPEPw86tM9dW2bK_w5DNLwU7yX7SOTYNvcR9g71vN9kqaW7vMWa-zf4MTe-Tkt2WDYYu-viVHNSuiXj0fM_I6tfVan5NF8vfN_OLBS21zHtamhxlBdLlHCrN1rJWIFIFdaXMWtdaIZdQa8NQ6tzkIFgJhU6nccLVckbOR9v9sN5hVWLbB9fYffA7F_7Zznn7Xmn9nd10f60GISAXyeDHs0Ho7geMvd35WKZVXYvdEC03HEwumWIJPf6AbrshtGm7RIHSko2GfKTK9A8xYP36GM7sU1R2jMqmqOxTVFalnu9vt3jteMkmAWIEYpLaDYY3o__r-ggJu50g</recordid><startdate>20171001</startdate><enddate>20171001</enddate><creator>Gelfand, Jeffrey M.</creator><creator>Cree, Bruce A. C.</creator><creator>Hauser, Stephen L.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20171001</creationdate><title>Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis</title><author>Gelfand, Jeffrey M. ; Cree, Bruce A. C. ; Hauser, Stephen L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c536t-c96e3d73a617d50b3f4727d57fd49b5f54e137f590e35696720c78520c9a2af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antigens, CD20 - immunology</topic><topic>B-Lymphocytes - drug effects</topic><topic>B-Lymphocytes - immunology</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>CD20 antigen</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Disease Progression</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Immunomodulators</topic><topic>Immunotherapy</topic><topic>Lymphocytes B</topic><topic>Monoclonal antibodies</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple Sclerosis - immunology</topic><topic>Neurobiology</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Neurosurgery</topic><topic>Review</topic><topic>Rituximab</topic><topic>Targeted cancer therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gelfand, Jeffrey M.</creatorcontrib><creatorcontrib>Cree, Bruce A. C.</creatorcontrib><creatorcontrib>Hauser, Stephen L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neurotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gelfand, Jeffrey M.</au><au>Cree, Bruce A. C.</au><au>Hauser, Stephen L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis</atitle><jtitle>Neurotherapeutics</jtitle><stitle>Neurotherapeutics</stitle><addtitle>Neurotherapeutics</addtitle><date>2017-10-01</date><risdate>2017</risdate><volume>14</volume><issue>4</issue><spage>835</spage><epage>841</epage><pages>835-841</pages><issn>1933-7213</issn><issn>1878-7479</issn><eissn>1878-7479</eissn><abstract>Selective depletion of CD20
+
B cells by anti-CD20 monoclonal antibodies as monotherapy in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and signifies an important advance in the treatment of relapsing-remitting MS. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, is also the first proven therapy to lessen disability progression in primary progressive MS—a breakthrough for patients with a disease that had no proven therapy. Ocrelizumab is generally well tolerated, with the most common adverse events experienced being infusion reactions and infections. In ocrelizumab trials in MS a numerical imbalance in the risk of malignancies was observed. In this article, we review advances in anti-CD20 B-cell-depleting biological therapies for MS, including ocrelizumab, rituximab, and ofatumumab.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>28695471</pmid><doi>10.1007/s13311-017-0557-4</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1933-7213 |
| ispartof | Neurotherapeutics, 2017-10, Vol.14 (4), p.835-841 |
| issn | 1933-7213 1878-7479 1878-7479 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5722762 |
| source | MEDLINE; SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Antibodies, Monoclonal, Humanized - therapeutic use Antigens, CD20 - immunology B-Lymphocytes - drug effects B-Lymphocytes - immunology Biomedical and Life Sciences Biomedicine CD20 antigen Clinical trials Clinical Trials as Topic Disease Progression Humans Immunologic Factors - therapeutic use Immunomodulators Immunotherapy Lymphocytes B Monoclonal antibodies Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis - immunology Neurobiology Neurology Neurosciences Neurosurgery Review Rituximab Targeted cancer therapy Treatment Outcome |
| title | Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T03%3A12%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ocrelizumab%20and%20Other%20CD20+%20B-Cell-Depleting%20Therapies%20in%20Multiple%20Sclerosis&rft.jtitle=Neurotherapeutics&rft.au=Gelfand,%20Jeffrey%20M.&rft.date=2017-10-01&rft.volume=14&rft.issue=4&rft.spage=835&rft.epage=841&rft.pages=835-841&rft.issn=1933-7213&rft.eissn=1878-7479&rft_id=info:doi/10.1007/s13311-017-0557-4&rft_dat=%3Cproquest_pubme%3E1917963040%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1974530762&rft_id=info:pmid/28695471&rfr_iscdi=true |